{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:14:47Z","timestamp":1783998887274,"version":"3.55.0"},"reference-count":133,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple myeloma (MM) is the second most common hematologic malignancy in the world. Even though survival rates have significantly risen over the past years, MM remains incurable, and is also far from reaching the point of being managed as a chronic disease. This paper reviews the evolution of MM therapies, focusing on anti-MM drugs that target the molecular mechanisms of nuclear factor kappa B (NF-\u03baB) signaling. We also provide our perspectives on contemporary research findings and insights for future drug development.<\/jats:p>","DOI":"10.3390\/cancers12082203","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T09:41:21Z","timestamp":1596706881000},"page":"2203","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Targeting NF-\u03baB Signaling for Multiple Myeloma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5960-9940","authenticated-orcid":false,"given":"Ada Hang-Heng","family":"Wong","sequence":"first","affiliation":[{"name":"Laboratory of NF-\u03baB Signaling, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore"},{"name":"AW Medical Company Limited, Macau, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-6772","authenticated-orcid":false,"given":"Eun Myoung","family":"Shin","sequence":"additional","affiliation":[{"name":"Laboratory of NF-\u03baB Signaling, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Tergaonkar","sequence":"additional","affiliation":[{"name":"Laboratory of NF-\u03baB Signaling, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore"},{"name":"Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore"},{"name":"Department of Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"Cancer Science Institute of Singapore, Singapore 117599, Singapore"},{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore"},{"name":"Department of Hematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore 119074, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kazandjian, D. (2016). Multiple myeloma epidemiology and survival: A unique malignancy. Seminars in Oncology, WB Saunders.","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: Results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"ref_5","unstructured":"Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2020, May 03). SEER Cancer Statistics Review (1975\u20132017), Bethesda, Available online: https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.molmed.2016.03.002","article-title":"Noncanonical NF-\u03baB Signaling in Health and Disease","volume":"22","author":"Cildir","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/biomedicines6030082","article-title":"Evidence for the involvement of the master transcription factor NF-\u03baB in cancer initiation and progression","volume":"6","author":"Puar","year":"2018","journal-title":"Biomedicines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.molmed.2017.11.003","article-title":"Noncoding RNAs: Master Regulators of Inflammatory Signaling","volume":"24","author":"Chew","year":"2018","journal-title":"Trends Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: Basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bergsagel, P.L., Nardini, E., Brents, L., Chesi, M., and Kuehl, W.M. (1997). IgH translocations in multiple myeloma: A nearly universal event that rarely involves c-myc. Current Topics in Microbiology and Immunology, Springer.","DOI":"10.1007\/978-3-642-60801-8_30"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18632\/oncotarget.109","article-title":"A critical role for the NF\u03baB pathway in multiple myeloma","volume":"1","author":"Demchenko","year":"2010","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Flynt, E., Bisht, K., Sridharan, V., Ortiz, M., Towfic, F., and Thakurta, A. (2020). Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9020287"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous Mutations Activate the Noncanonical NF-\u03baB Pathway in Multiple Myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-04-3589","article-title":"Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation","volume":"65","author":"Hodge","year":"2005","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3389\/fonc.2018.00566","article-title":"The epigenome in multiple myeloma: Impact on tumor cell plasticity and drug response","volume":"8","author":"Lui","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Iannetti, A., Ledoux, A.C., Tudhope, S.J., Sellier, H., Zhao, B., Mowla, S., Moore, A., Hummerich, H., Gewurz, B.E., and Cockell, S.J. (2014). Regulation of p53 and Rb Links the Alternative NF-\u03baB Pathway to EZH2 Expression and Cell Senescence. PLoS Genet., 10.","DOI":"10.1371\/journal.pgen.1004642"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","article-title":"Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition","volume":"23","author":"Rizq","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4049\/jimmunol.1701470","article-title":"EZH2 Represses the B Cell Transcriptional Program and Regulates Antibody-Secreting Cell Metabolism and Antibody Production","volume":"200","author":"Guo","year":"2018","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent Engagement of the Classical and Alternative NF-\u03baB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-\u03baB pathway activation in multiple myeloma","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pires, B.R.B., Silva, R.C.M.C., Ferreira, G.M., and Abdelhay, E. (2018). NF-kappaB: Two sides of the same coin. Genes, 9.","DOI":"10.3390\/genes9010024"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.trecan.2020.04.003","article-title":"NF-\u03baB in the New Era of Cancer Therapy","volume":"6","author":"Eluard","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clml.2018.03.007","article-title":"Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways","volume":"18","author":"Dehghanifard","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","article-title":"30 Years of NF-kB: A Blossoming of Relevance to Human Pathobiology","volume":"168","author":"Zhang","year":"2017","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/cr.2010.161","article-title":"A single NF\u03baB system for both canonical and non-canonical signaling","volume":"21","author":"Shih","year":"2011","journal-title":"Cell Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-\u03baB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14402","DOI":"10.1073\/pnas.1611106113","article-title":"Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas","volume":"113","author":"Li","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.febslet.2015.02.035","article-title":"Quantitative assessment of telomerase components in cancer cell lines","volume":"589","author":"Akincilar","year":"2015","journal-title":"FEBS Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13082-9","article-title":"Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy","volume":"10","author":"Khattar","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ozturk, M.B., Li, Y., and Tergaonkar, V. (2017). Current insights to regulation and role of telomerase in human diseases. Antioxidants, 6.","DOI":"10.3390\/antiox6010017"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1084\/jem.20170910","article-title":"The transcriptional program, functional heterogeneity, and clinical targeting of mast cells","volume":"214","author":"Cildir","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/bjc.2014.422","article-title":"Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells","volume":"111","author":"Siveen","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.270.5234.286","article-title":"Immunosuppression by glucocorticoids: Inhibition of NF-\u03baB activity through induction of I\u03baB synthesis","volume":"270","author":"Auphan","year":"1995","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4049\/jimmunol.1800158","article-title":"Dual Roles for Ikaros in Regulation of Macrophage Chromatin State and Inflammatory Gene Expression","volume":"201","author":"Oh","year":"2018","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Udeshi","year":"2014","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.intimp.2011.12.023","article-title":"Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro\u22efA possible explanation for their mechanism of action in treating multiple myeloma","volume":"12","author":"Shannon","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"20394","DOI":"10.18632\/oncotarget.14610","article-title":"Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression","volume":"8","author":"Mondello","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2008-03-145169","article-title":"The role of Dickkopf-1 in bone development, homeostasis, and disease","volume":"113","author":"Pinzone","year":"2009","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/10428190500066636","article-title":"Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1\u03b1) in human multiple myeloma","volume":"46","author":"Hata","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","article-title":"Genetic events in the pathogenesis of multiple myeloma","volume":"20","author":"Chng","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/intimm\/dxf072","article-title":"NF-kB is required for CD38-mediated induction of Cg1 germline transcripts in murine B. lymphocytes","volume":"14","author":"Kaku","year":"2002","journal-title":"Int. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/8736949","article-title":"CD38 Deficiency Promotes Inflammatory Response Through Activating Sirt1\/NF-\u03baB-Mediated Inhibition of TLR2 Expression in Macrophages","volume":"2018","author":"Qian","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in Patients with Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12013-014-0224-x","article-title":"Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy","volume":"71","author":"Li","year":"2014","journal-title":"Cell Biochem. Biophys."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1182\/blood.V126.23.5365.5365","article-title":"Infection Complications in 476 Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide or Bortezomib Combinations","volume":"126","author":"Offidani","year":"2015","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Prescott, J., and Cook, S. (2018). Targeting IKK\u03b2 in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKK\u03b2 Inhibitors. Cells, 7.","DOI":"10.3390\/cells7090115"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3324\/haematol.2017.185264","article-title":"Denosumab for bone lesions in multiple myeloma\u2014What is its value?","volume":"103","author":"Goldstein","year":"2018","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-B, inflammation, immunity and cancer: Coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ni.2060","article-title":"Inflammation meets cancer, with NF-\u03baB as the matchmaker","volume":"12","author":"Karin","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"27326","DOI":"10.1074\/jbc.M112.366658","article-title":"Structure of the nuclear factor \u03baB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.18632\/oncotarget.2128","article-title":"Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB","volume":"5","author":"Demchenko","year":"2014","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.str.2008.02.012","article-title":"Structure of a NEMO\/IKK-Associating Domain Reveals Architecture of the Interaction Site","volume":"16","author":"Rushe","year":"2008","journal-title":"Structure"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Habineza Ndikuyeze, G., Gaurnier-Hausser, A., Patel, R., Baldwin, A.S., May, M.J., Flood, P., Krick, E., Propert, K.J., and Mason, N.J. (2014). A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095404"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1038\/s41467-018-05644-0","article-title":"Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1","volume":"9","author":"Xu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14656566.2017.1349102","article-title":"Melphalan hydrochloride for the treatment of multiple myeloma","volume":"18","author":"Esma","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"Szmania","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better?","volume":"34","author":"Raje","year":"2020","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e1254856","DOI":"10.1080\/2162402X.2016.1254856","article-title":"PD-1\/PD-L1 inhibitors in multiple myeloma: The present and the future","volume":"5","author":"Jelinek","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Gowrishankar, K., Gunatilake, D., Gallagher, S.J., Tiffen, J., Rizos, H., and Hersey, P. (2015). Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-\u03baB. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123410"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1021\/acs.jmedchem.8b00678","article-title":"Scaffold-Hopping Approach to Discover Potent, Selective, and Efficacious Inhibitors of NF-\u00ceB Inducing Kinase","volume":"61","author":"Blaquiere","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e1800374","DOI":"10.1002\/ardp.201800374","article-title":"Identification of new NIK inhibitors by discriminatory analysis-based molecular docking and biological evaluation","volume":"352","author":"Cheng","year":"2019","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"115316","DOI":"10.1016\/j.bone.2020.115316","article-title":"A novel inhibitor of NF-\u03baB-inducing kinase prevents bone loss by inhibiting osteoclastic bone resorption in ovariectomized mice","volume":"135","author":"Takakura","year":"2020","journal-title":"Bone"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1021\/acs.jmedchem.0c00396","article-title":"Discovery of a Potent and Selective NF-\u03baB-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"ref_88","first-page":"CD010816","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/17474086.2020.1729734","article-title":"Real-world outcomes and factors impacting treatment choice in relapsed and\/or refractory multiple myeloma (RRMM): A comparison of VRd, KRd, and IRd","volume":"13","author":"Chari","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2018-06-860015","article-title":"Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR","volume":"133","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1470-2045(17)30613-7","article-title":"Carfilzomib versus bortezomib: No longer an ENDEAVOR","volume":"18","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Shin, E.M., Neja, S.A., Fidan, K., Chua, J.Y.H., Chung, T., Bertin, N., Tergaonkar, V., Chng, W., and Ooi, M.G. (2020). Lymphocyte cytosolic protein 1 (LCP1) is a novel TRAF3 dysregulation biomarker with potential prognostic value in multiple myeloma. Genome Instab. Dis.","DOI":"10.1007\/s42764-020-00014-x"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ni.1676","article-title":"Noncanonical NF-\u03baB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK","volume":"9","author":"Zarnegar","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/ni.1678","article-title":"Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-\u03baB signaling","volume":"9","author":"Vallabhapurapu","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"ra88","DOI":"10.1126\/scisignal.aaa5157","article-title":"The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development","volume":"8","author":"Lin","year":"2015","journal-title":"Sci. Signal."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep35349","article-title":"TRAF3 deficiency promotes metabolic reprogramming in B cells","volume":"6","author":"Mambetsariev","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1073\/pnas.1514586113","article-title":"Nuclear TRAF3 is a negative regulator of CREB in B cells","volume":"113","author":"Mambetsarieva","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.immuni.2007.07.012","article-title":"Tumor Necrosis Factor Receptor-Associated Factor 3 Is a Critical Regulator of B Cell Homeostasis in Secondary Lymphoid Organs","volume":"27","author":"Xie","year":"2007","journal-title":"Immunity"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"29911","DOI":"10.1074\/jbc.M109.099697","article-title":"Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts","volume":"285","author":"Ma","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Chellaiah, M.A., Majumdar, S., and Aljohani, H. (2018). Peptidomimetic inhibitors of L-plastin reduce the resorptive activity of osteoclast but not the bone forming activity of osteoblasts in vitro. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204209"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.tranon.2018.11.014","article-title":"Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis","volume":"12","author":"Tiedemann","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/ijc.22589","article-title":"Phosphorylation of ectopically expressed L-plastin enhances invasiveness of human melanoma cells","volume":"120","author":"Klemke","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1074\/mcp.M114.046110","article-title":"Proteotranscriptomic profiling of 231-BR breast cancer cells: Identification of potential biomarkers and therapeutic targets for brain metastasis","volume":"14","author":"Dun","year":"2015","journal-title":"Mol. Cell. Proteom."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"33648","DOI":"10.18632\/oncotarget.5203","article-title":"GLI1 orchestrates CXCR4\/CXCR7 signaling to enhance migration and metastasis of breast cancer cells","volume":"6","author":"Inaguma","year":"2015","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1006\/bbrc.2001.6047","article-title":"Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis","volume":"289","author":"Otsuka","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1002\/ijc.21593","article-title":"The leukocyte protein L-plastin induces proliferation, invasion and loss of E-cadherin expression in colon cancer cells","volume":"118","author":"Foran","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/1535-7163.MCT-13-0646","article-title":"Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy","volume":"13","author":"Ning","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.4238\/2013.May.6.1","article-title":"Gene expression profile and enrichment pathways in different stages of bladder cancer","volume":"12","author":"Fang","year":"2013","journal-title":"Genet. Mol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1055-9965.EPI-12-1156","article-title":"Composite three-marker assay for early detection of kidney cancer","volume":"22","author":"Kim","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2013-05-504597","article-title":"Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"111498","DOI":"10.1016\/j.yexcr.2019.111498","article-title":"Reduced exosomal L-Plastin is responsible for radiation-induced bystander effect","volume":"383","author":"Freudenmann","year":"2019","journal-title":"Exp. Cell Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/ijms19061551","article-title":"Inhibition of HIF1\u03b1-dependent upregulation of phospho-L-Plastin resensitizes multiple myeloma cells to frontline therapy","volume":"19","author":"Bosseler","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6943986","DOI":"10.1155\/2019\/6943986","article-title":"Engineering of L-Plastin Peptide-Loaded Biodegradable Nanoparticles for Sustained Delivery and Suppression of Osteoclast Function In Vitro","volume":"2019","author":"Majumdar","year":"2019","journal-title":"Int. J. Cell Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1084\/jem.20051591","article-title":"PKC\u03b2 regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1","volume":"202","author":"Shinohara","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/ni.1666","article-title":"Tonic B cell antigen receptor signals supply an NF-\u03baB substrate for prosurvival BLyS signaling","volume":"9","author":"Stadanlick","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"10758","DOI":"10.1038\/srep10758","article-title":"Catalytic subunits of the phosphatase calcineurin interact with NF-\u03baB-inducing kinase (NIK) and attenuate NIK-dependent gene expression","volume":"5","author":"Shinzawa","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/eji.1830201017","article-title":"Suppression of B cell activation by cyclosporin A, FK506 and rapamycin","volume":"20","author":"Wicker","year":"1990","journal-title":"Eur. J. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1016\/S1470-2045(13)70404-2","article-title":"Management of multiple myeloma in Asia: Resource-stratified guidelines","volume":"14","author":"Tan","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.13197","article-title":"NFKB1 -94ins\/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma","volume":"168","author":"Varga","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2010-07-298349","article-title":"The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t (4;14) multiple myeloma cells","volume":"117","author":"Popovic","year":"2011","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"13750","DOI":"10.1074\/jbc.RA118.004274","article-title":"High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2","volume":"293","author":"Coussens","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00001813-199212000-00013","article-title":"SDZ PSC-833\u2014A novel potent in vitro chemosensitizer in multiple myeloma","volume":"3","author":"Jonsson","year":"1992","journal-title":"Anticancer Drugs"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cncr.21666","article-title":"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar\/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group","volume":"106","author":"Friedenberg","year":"2006","journal-title":"Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/cancers12051065","article-title":"Nelfinavir Inhibits the TCF11\/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma","volume":"12","year":"2020","journal-title":"Cancers"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1309\/AJCPOP7APGDT9JIU","article-title":"Myeloid neoplasms secondary to plasma cell myeloma: An intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens","volume":"138","author":"Reddi","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MOH.0b013e32835d82e6","article-title":"Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia","volume":"20","author":"Klimek","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clml.2014.07.001","article-title":"Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_133","first-page":"e13050","article-title":"Increasing therapy-related myeloid neoplasms in multiple myeloma","volume":"49","author":"Hurtado","year":"2018","journal-title":"Eur. J. Clin. Investig."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2203\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:57:16Z","timestamp":1760176636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":133,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082203"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082203","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]}}}